Oct. 6, 2023: State Advocacy Update

| 2 Min Read

WisMed, WISAM, AMA oppose bill authorizing the sale and marketing of kratom

It is inappropriate to authorize the sale, marketing or distribution of kratom given that the FDA has not approved any prescription or over-the-counter drug products containing kratom or its two main chemical components, the AMA wrote (PDF) in opposition to Wisconsin Assembly Bill 393 (AB 393). The AMA joined the Wisconsin Medical Society (WisMed) and Wisconsin Society of Addiction Medicine (WISAM) in opposing AB 393.

Haven't subscribed?

Stay current on the latest on the issues impacting physicians, patients and the healthcare environment with the AMA’s Advocacy Update newsletter.

“We have seen an increasing number of deaths associated with kratom the longer that it has been available in the U.S. market,” testified (PDF) WISAM President Ritu Bhatnagar, MD, speaking on behalf of WISAM and WisMed in opposition to AB 393. Dr. Bhatnagar also outlined a wide range of health risks associated with kratom use, including overdose and death.   

“Current research supporting kratom’s medical benefits is insufficient to justify its substantial risk to consumers,” said Dr. Bhatnagar. “There is no evidence that kratom (or its alkaloids) is an appropriate treatment for opioid use disorder.”

Your Powerful Ally

Through AMA advocacy and policymaking, we are addressing the issues important to you—together—and shaping what’s next for physicians.

FEATURED STORIES

Physician looking out a window

Physicians in these 10 specialties are less likely to quit

| 6 Min Read
Perturbed patient holds up hands during an appointment

Only 1 in 3 doctors trusts insurers’ prior authorization promises

| 6 Min Read
Senior man looks off into the distance

As population ages, need for practicing geriatricians grows more acute

| 5 Min Read
Jason Mitchell, MD, featured on "Health vs. Hype" AMA podcast (episode 3)

9 things patients should know about taking creatine

| 5 Min Read